Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBIT: 2020-2024

Historic EBIT for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to -$98.8 million.

  • Janux Therapeutics' EBIT rose 1.65% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.3 million, marking a year-over-year decrease of 67.85%. This contributed to the annual value of -$98.8 million for FY2024, which is 35.45% down from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' EBIT is -$98.8 million, which was down 35.45% from -$73.0 million recorded in FY2023.
  • Janux Therapeutics' 5-year EBIT high stood at -$4.8 million for FY2020, and its period low was -$98.8 million during FY2024.
  • Over the past 3 years, Janux Therapeutics' median EBIT value was -$73.0 million (recorded in 2023), while the average stood at -$79.6 million.
  • Data for Janux Therapeutics' EBIT shows a maximum YoY crashed of 579.93% (in 2021) over the last 5 years.
  • Janux Therapeutics' EBIT (Yearly) stood at -$4.8 million in 2020, then crashed by 579.93% to -$32.9 million in 2021, then plummeted by 103.74% to -$67.1 million in 2022, then declined by 8.78% to -$73.0 million in 2023, then plummeted by 35.45% to -$98.8 million in 2024.